STOCKHOLM, Sweden--(BUSINESS WIRE)--Regualatory News:
The number of shares and votes in Wilson Therapeutics AB (publ) has changed as a result of the new issue of shares that was made based on the over-allotment option granted in connection with the listing of the company’s shares on Nasdaq Stockholm. Today, the last trading day of the month, there are in total 25,720,248 shares and votes in Wilson Therapeutics.
About Wilson Therapeutics Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ lead product, Decuprate®, is initially being developed as a novel treatment for Wilson Disease and is currently being evaluated in a Phase II clinical study. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.
Visit www.wilsontherapeutics.com for more information.
Wilson Therapeutics AB (publ) Org nr 556893-0357 Västra Trädgårdsgatan 15 SE-111 53 Stockholm
The information in the press release is such that Wilson Therapeutics is required to disclose publicly in accordance with the Swedish Financial Instruments Trading Act. The information was submitted for publication on June 30, 2016 at 8.00 a.m.
This information was brought to you by Cision http://news.cision.com
For further information contact:
Anders Martin-Löf, CFO, Wilson
Therapeutics AB
Telephone: +46 8 796 00 00
Email: anders.martin-lof@wilsontx.eu
